Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This article suggests that a topical sulfonylurea drug may inhibit excessive hair growth caused by diazoxide without affecting its beneficial effects on beta cells, potentially offering a treatment for various forms of hypertrichosis and hirsutism.

This study found that the retinoic acid derivative Ro 10-9359 cleared psoriasis lesions in over half of the patients, but most experienced side effects, including skin issues and altered liver enzyme levels.

In this study, researchers developed a novel delivery system using hyaluronic acid gels to encapsulate Huperzine A for Alzheimer's treatment, achieving extended release over 20 days and significantly improving pathology and behavior in mice, including enhanced memory and reduced neuroinflammation.

In this study, metformin, pioglitazone, and ethinylestradiol cyproterone all improved various clinical features and quality of life in Pakistani women with PCOS, though no drug significantly reduced hirsutism.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

This article reviews the uses, mechanisms, and side effects of valproate in treating bipolar disorder, noting its first-line status for several manic conditions but also highlighting serious risks such as fetal abnormalities.

In this study, researchers found that female rats exhibited more pronounced panic-related escape behavior during hypoxia, particularly in the diestrus phase, and that low-dose fluoxetine reduced this behavior, suggesting its potential for managing panic disorder symptoms related to hormonal cycles in women.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This study found no significant difference in anagen rate improvement between the CYP-based dietary supplement and placebo in women over 60 with telogen effluvium, possibly due to variable patient inclusion related to hair growth seasonality.

This study found that an extract treatment showed similar efficacy and tolerability to calcipotriol/betamethasone ointment in reducing psoriasis severity and symptoms over 28 days in patients with mild-to-moderate plaque psoriasis.

This review discusses the challenges of diagnosing and treating pediatric bipolar disorder and highlights the potential benefits of combined psychopharmacological treatments, noting no long-term efficacy from mood stabilizer monotherapy.

Gepant medications for migraines show varied safety profiles in this study, with specific adverse events reported across systems like gastrointestinal and skin disorders, highlighting the need for tailored treatment and monitoring.

In this case report, a 60-year-old woman with alopecia areata and type 1 diabetes experienced hypoglycemic seizures after starting baricitinib, though reducing the dose alleviated these episodes; the study highlights the need for caution and glucose monitoring when using JAK inhibitors in at-risk patients.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

This study found that bupropion was associated with a higher risk of hair loss compared to other antidepressants, with paroxetine presenting the lowest risk.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

This review discusses the therapeutic use of insulin-sensitizing agents in polycystic ovary syndrome, reporting improved ovulation, insulin sensitivity, and reduction of hyperandrogenism, but calls for larger studies to confirm these effects.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This study found that omeprazole can cause acquired generalized hypertrichosis by significantly increasing duodenal prostaglandin E2 synthesis, which is involved in hair growth regulation.

This study identified certain benzopyran derivatives with a bulky tert-butyloxycarbonylamino group as effective KATP channel openers that inhibit insulin secretion in rat pancreatic islets.

This report describes the first known case of alopecia in a 16-year-old patient associated with quetiapine use, which resolved after stopping the medication.

This study found that combining liraglutide with metformin led to greater weight loss and waist circumference reduction than either treatment alone in obese women with PCOS resistant to metformin monotherapy.